Lokiec F, Santoni J, Weill S, Tubiana-Hulin M
Department of Pharmacology, Centre René Huguenin, Saint-Cloud, France.
Anticancer Drugs. 1996 Nov;7(8):893-6. doi: 10.1097/00001813-199611000-00013.
Ten patients (three males and seven females) were treated for sarcoma with high-dose ifosfamide (IFO) according to a 4 g/m2 1 h i.v. infusion schedule every day for 3 days. The courses were repeated every 4 weeks. Phenobarbital (PB) treatment was only started at the second course and was continued for the following courses at a p.o. dose of 60 mg/ day on the 3 days of IFO i.v. infusion. IFO pharmacokinetic studies were performed on the first and third day of each course. The results of the pharmacokinetic analysis showed a statistical difference of the IFO parameters between the first and third day of each course with or without PB co-administration. When we compared all the first days and all the third days, the statistical analysis showed no difference for all the pharmacokinetic parameters. The meaning of these results was that IFO kinetics was not stationary with an area under the curve decreasing from the first to the third day of each course and that concomitant PB administration, in our administration schedule, did not influence IFO pharmacokinetics.
10例患者（3例男性，7例女性）接受了高剂量异环磷酰胺（IFO）治疗肉瘤，按照每天4g/m²静脉输注1小时的方案，持续3天。疗程每4周重复一次。苯巴比妥（PB）治疗仅在第二个疗程开始，并在随后的疗程中继续，在IFO静脉输注的3天中口服剂量为60mg/天。在每个疗程的第一天和第三天进行IFO药代动力学研究。药代动力学分析结果显示，每个疗程的第一天和第三天，无论是否联合使用PB，IFO参数均存在统计学差异。当我们比较所有第一天和所有第三天时，统计分析显示所有药代动力学参数均无差异。这些结果的意义在于，IFO动力学不稳定，每个疗程从第一天到第三天曲线下面积减小，并且在我们的给药方案中，联合使用PB不影响IFO药代动力学。
